Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Analgesic

or Antidepressant

or Beta Blocker

Use the filters below to narrow your results.

Codeine (2)

None (6) · (multiple, generic dominant) (1) · Anafranil (1) · Aurorix (1) · Betapace (1) · Brevibloc (1) · Bystolic (1) · Corgard (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Dolophine (1) · Duragesic (1) · Edronax (1) · Fetzima (1) · Inderal (1) · Lopressor (tartrate), Toprol XL (succinate) (1) · Ludiomil (1) · Marplan (1) · Nardil (1) · Norpramin (1) · Nubain (1) · Nucynta (1) · Opana (1) · Parnate (1) · Savella (1) · Serzone (1) · Stablon (1) · Stadol (1) · Suboxone (1) · Surmontil (1) · Talwin (1) · Tofranil (1) · Valdoxan (1) · Vicodin (1) · Vivactil (1) · Zebeta (1) · Zoloft (1)

None (3) · Cardioselective β1-adrenergic antagonist. Selectivity is dose-dependent and partially lost at higher doses. (1) · Highly β1-selective adrenergic antagonist. Greater selectivity than metoprolol or atenolol. (1) · Irreversible non-selective MAO inhibitor (3) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Melatonin receptor agonist; 5-HT2C antagonist (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; NMDA antagonist (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Non-selective competitive antagonist at β1 and β2 adrenergic receptors. Lipophilic; significant blood–brain barrier penetration, accounting for its CNS effects. (1) · Partial mu-opioid agonist; kappa antagonist (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (3) · Potent serotonin reuptake inhibitor; also NRI (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Reversible inhibitor of MAO-A (1) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin reuptake inhibitor and 5-HT2A antagonist (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Serotonin–norepinephrine reuptake inhibitor (2) · The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism. (1) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Weak SRI; primarily H1/D2/alpha antagonist (1)

None (38) · 10–40 mg (situational anxiety); 40 mg BID (HTN) (1) · 2.5–5 mg daily (HTN); 1.25 mg daily (HFrEF, slow titration) (1) · 25 mg (1) · 25–50 mg BID (tartrate); 25–100 mg daily (succinate); 12.5 mg daily in HFrEF (1) · 5 mg daily (1) · Adult: 15–60 mg every 4 hours as needed. (1)

None (38) · 10, 20, 40, 60, 80 mg tabs; 60/80/120/160 mg ER caps; 1 mg/mL IV (1) · 2.5, 5, 10, 20 mg tabs (1) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · 5, 10 mg tabs (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1) · Tartrate: 25, 50, 100 mg tabs; 1 mg/mL IV. Succinate ER: 25, 50, 100, 200 mg. (1)

None (38) · 20 mg/d (1) · 200 mg/d (1) · 360 mg/day (1) · 40 mg/d (1) · 400 mg/d (1) · 640 mg/d (HTN); 240 mg/d (migraine) (1)

None (37) · IV (2) · Oral (6) · PO (only formulation marketed in the US). (1)

None (37) · 1–2 h (2) · 1–2 h (PO), immediate (IV) (1) · 1–2 h (PO); immediate (IV) (1) · 30–60 min (PO) (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1)

None (37) · 24 h (2) · 4–6 hours (1) · 6–12 h (IR); 24 h (ER) (1) · 6–12 h (tartrate); 24 h (succinate) (1) · Chronic daily dosing (1) · Long (1)

None (37) · 2.5–3 hours (1) · 3–6 h (1) · 3–7 h (1) · 9–12 h (1) · ~10 h (CYP2D6 extensive metabolizers); up to 31 h (poor metabolizers) (1) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)

None (37) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · ~12% (extensive metabolizers); ~96% (poor metabolizers) (1) · ~25% (extensive hepatic first-pass) (1) · ~50% (1) · ~50% (highly variable) (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~90% (low first-pass) (1)

None (37) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Category C (5) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1)

None (37) · Rx-only (1) · Rx-only in US (5) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)